Guggul
Best-in-class: Guggul
An Ayurvedic resin used for lipids and thyroid. Independent trials did not confirm the traditional lipid claim.
Guggul quick facts
| Suggested dose | Not recommended on current evidence. |
| How often | Not recommended on current evidence |
| Who it's for | Nobody, for lipids. |
The lipid evidence has not held up — a well-conducted American trial found guggul actually raised LDL, contradicting the earlier Indian data. The thyroid effect is rodent-level. The bigger practical issue is drug interaction: guggul induces CYP3A4 and P-glycoprotein and reduces levels of propranolol, diltiazem and others. Hard to justify given the evidence and the interactions.
How Guggul actually works
Guggulsterones antagonize the farnesoid X receptor, which increases hepatic conversion of cholesterol to bile acids and is the basis of the lipid effect. Separately they increase T4-to-T3 conversion in rodents, which is the thyroid rationale.
Where to get Guggul
Find Guggul on iHerb →The evidence for Guggul
Graded by what exists behind each claim.
✅ Clinically validated
- A well-conducted US randomized trial found guggul did NOT lower LDL and in some participants raised it. Earlier positive results came largely from a single regional literature.
📊 Correlative data
- Used in Ayurveda for obesity and lipid complaints for well over two thousand years, and it was on that basis that the lipid trials were run. Those trials were largely disappointing in Western populations, and the divergence between the traditional claim and the trial result is the honest headline.
🧪 Theoretical / extrapolated benefits
- Guggulsterones antagonize the farnesoid X receptor, which is a real mechanism with an unclear net direction in humans.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Guggul actually does
Guggul is the oleogum resin of Commiphora mukul, and the molecules the pharmacology belongs to are the guggulsterones — the E and Z isomers of 4,17(20)-pregnadiene-3,16-dione. That name is worth reading slowly, because a pregnadienedione is a steroid. This is not a polyphenol or a terpene doing something vaguely membrane-shaped. It is a plant molecule with a steroid nucleus, and every surprise on this page follows from that.
The target it is famous for is the farnesoid X receptor, and the logic is genuinely elegant. FXR is the nuclear receptor that senses bile acids. When bile acids activate it, FXR induces the small heterodimer partner, which shuts down transcription of CYP7A1 — cholesterol 7-alpha-hydroxylase, the rate-limiting enzyme that converts cholesterol into bile acid. That is a feedback loop: enough bile acid, stop making more. Antagonize FXR and you cut the brake line. CYP7A1 is de-repressed, hepatic cholesterol is pulled into bile acid synthesis, and the liver replaces it by pulling LDL out of plasma. A cholesterol-lowering herb whose mechanism is an FXR antagonist is a beautiful story, and Urizar and colleagues published it in Science Urizar 2002.
And they proved it genetically, which almost nobody does. Guggulsterone lowered hepatic cholesterol in wild-type mice fed a high-cholesterol diet, and had no effect in FXR-null mice Urizar 2002. Delete the receptor and the effect disappears. That is the strongest form of mechanistic evidence available short of a human trial, and it is the reason this compound was taken seriously.
Then a second nuclear receptor turned up, pointing the other way. Guggulsterone antagonizes FXR induction of the bile salt export pump, but it activates the pregnane X receptor — and PXR activation inhibits CYP7A1 transcription Owsley 2003. Read those two sentences together. Through FXR, guggulsterone turns CYP7A1 up. Through PXR, the same molecule turns CYP7A1 down. One compound, two nuclear receptors, opposite signs on the same enzyme. Nothing about the FXR result is wrong; it is simply not the whole account, and the net direction in a liver depends on which receptor is better occupied there.
The number that should end the marketing is a binding constant. When guggulsterone was screened across the steroid receptor family, both stereoisomers bound the mineralocorticoid receptor with a Ki of about 35 nM — more than a hundred times more potent than their affinity for FXR. Androgen, glucocorticoid and progesterone receptors came in at Ki 224 to 315 nM, and estrogen receptor agonist activity needed an EC50 above 5,000 nM Burris 2005. So the receptor this compound binds best is not the receptor it is sold against. It is the aldosterone receptor, by two orders of magnitude, and no product label, no trial and no review of guggul for lipids has ever measured a mineralocorticoid endpoint.
The thyroid arm is older and it is not folklore either. Z-guggulsterone given to albino rats at 1 mg per 100 g of body weight for 28 days increased thyroidal iodine uptake, raised thyroid peroxidase activity, and raised oxygen consumption in isolated liver and muscle slices Tripathi 1984, with a follow-up paper working on the mechanism of that stimulation Tripathi 1988. Thyroid peroxidase is the enzyme that oxidizes iodide and couples iodotyrosines into T4 and T3. A compound that raises its activity is acting on hormone synthesis itself, not on some downstream metabolic proxy — and that, rather than the lipid claim, is the guggul mechanism with the cleanest enzyme behind it.
Cell, rodent, human — and where it stops
The dish and the mouse are strong, and that is exactly why the human result matters so much. Reporter assays and FXR-null mice give a mechanism that survives a genetic knockout Urizar 2002; rats given Z-guggulsterone at 1 mg/100 g body weight for 28 days give a thyroid enzyme effect Tripathi 1984. Nothing here is hand-waving. The step that fails is the last one.
The trial, with every number it reported. One hundred and three adults with hypercholesterolemia were randomized to standard-dose guggulipid, high-dose guggulipid or placebo — 1,000 mg or 2,000 mg three times daily — for eight weeks. In the placebo arm (n = 36) LDL cholesterol fell 5%. In the standard-dose arm (n = 33) LDL rose 4% (P = .01). In the high-dose arm (n = 34) LDL rose 5% (P = .006) Szapary 2003. Not “failed to fall”. Rose, against a placebo group that improved, at both doses, with p-values that are not borderline.
The second controlled trial is not a rescue either. Forty-three people aged 27 to 70 took 2,160 mg a day for 12 weeks. Total cholesterol fell significantly — and so did HDL cholesterol, while LDL and triglycerides did not move Nohr 2009. A total-cholesterol fall driven by losing HDL is the one way of lowering that number nobody wants. Ten participants reported adverse effects: seven gastrointestinal, two thyroid Nohr 2009.
So name the obstacle precisely, because it is not the usual one. It is not that the mechanism is fake — the knockout proves it is real Urizar 2002. It is not dose: 3 to 6 grams a day of guggulipid is more than anyone takes Szapary 2003. The obstacle is that a single molecule acts on two nuclear receptors that regulate the same gene in opposite directions Owsley 2003, and a knockout mouse answers the question “can FXR carry this effect?” while a human answers “what happens when every receptor is present at once?” Those are different questions, and only the second one is the purchase.
The second obstacle is which literature you are reading. The encouraging lipid results are older and come from outside the randomized Western trial base; the two placebo-controlled trials that measured LDL against a control arm are the ones summarized above, and neither reproduced the traditional claim Szapary 2003 Nohr 2009. This is the cleanest example on the site of a compound whose mechanism is better than its outcome, and the correct conclusion is not that mechanism is worthless. It is that a mechanism is a hypothesis, and this one was tested and lost.
Guggul — which form, and does it matter
Guggulipid is not gum guggul, and the two trials used different things. The crude oleogum resin is the traditional material; guggulipid is the ethyl-acetate-soluble fraction, concentrated for guggulsterones and stripped of most of the gum. The JAMA trial used guggulipid at 1,000 or 2,000 mg three times daily Szapary 2003; the Danish trial used 2,160 mg a day of the resin Nohr 2009. Different preparations, different doses, and both negative for LDL — which is the one thing that makes the preparation question less important here than it usually is.
What a label should tell you, and usually does not. The only specification with pharmacology attached is the guggulsterone percentage — the combined E and Z content. Everything measured in this file is a property of those two isomers Urizar 2002 Burris 2005 Owsley 2003. A capsule that says “guggul extract 500 mg” with no guggulsterone figure is telling you the weight of the powder, not the dose of the drug, and the extract ratio does not fix that because ratios are computed against a starting material nobody standardized either.
E versus Z is a real distinction, and it matters differently for each target. At the mineralocorticoid receptor the two isomers are equivalent — both bind at about 35 nM Burris 2005. The thyroid work, by contrast, was done specifically with Z-guggulsterone Tripathi 1984 Tripathi 1988. So a product standardized to “total guggulsterones” carries the steroid receptor activity of both isomers regardless of ratio, while the thyroid claim belongs to one of them and no retail label states the E:Z split.
The form question that would actually change the answer. Because FXR antagonism and PXR agonism cancel Owsley 2003, a derivative that kept the FXR antagonism and lost the PXR agonism would be a real drug candidate rather than a resin. That work belongs to medicinal chemistry, not to a supplement shelf, and it is the honest answer to “which guggul should I buy”: none of them, because the molecule that would work has not been made.
And one practical note about what else is in the resin. Gum guggul is a gum — largely polysaccharide — so a high-milligram, low-guggulsterone product is mostly indigestible carbohydrate, which is a plausible part of why gastrointestinal complaints dominate the adverse-event lists in both trials Szapary 2003 Nohr 2009. That is an inference from composition rather than a measured attribution, and it is labeled as one.
What would have to be true, and how you would know it was not
1. ldl cholesterol, and the predicted direction is up. On a retail dose for eight to twelve weeks, predict LDL unchanged or higher by roughly 4–5%, because that is what both guggulipid doses did against a placebo arm that improved 5% Szapary 2003. This is the rare supplement page where the prediction is that the marker moves the wrong way, and it is a prediction anyone can falsify for the price of a lipid panel.
2. hdl cholesterol, the marker nobody watches on this product. Predict HDL down at twelve weeks, which is what the 43-person trial found alongside its fall in total cholesterol Nohr 2009. If total cholesterol falls and HDL falls with it, the product has not improved anything; it has moved a number that people read carelessly.
3. tsh and free t4 — the prediction that cuts against this page's skepticism. Everything above says guggul fails at the thing it is sold for. The thyroid pharmacology is a different matter: Z-guggulsterone raises thyroid peroxidase activity and iodine uptake in rats Tripathi 1984, and two participants in the Danish trial reported thyroid-related adverse effects Nohr 2009. So predict, in a subset of users, free T4 up and TSH down at eight weeks — a genuine drug-like effect on an axis the product does not claim. Draw TSH, free T4 and free T3 before starting. If that prediction holds, guggul is pharmacologically active and simply mislabeled, which is a more interesting failure than being inert.
4. Blood pressure and potassium, from the binding constant, labeled as extrapolation. Guggulsterone binds the mineralocorticoid receptor at about 35 nM — a hundredfold tighter than FXR Burris 2005. Aldosterone signaling sets renal sodium retention and potassium excretion, so an MR-active compound should show up as a change in blood pressure and serum potassium before it shows up anywhere else. Predict a measurable shift in one of them on sustained dosing. No human study has ever looked, this follows from an in-vitro Ki rather than from any trial, and it is the single cheapest test on this page: a home blood-pressure log and one basic metabolic panel.
5. The skin, which is the endpoint that reports itself. Six participants on guggulipid developed a hypersensitivity rash against none on placebo Szapary 2003 — roughly one in eleven of the 67 people who took it. Predict rash at about that rate, within the first weeks. It needs no lab and it is the most reliably reproduced finding in the entire guggul trial literature.
What nobody has tested yet
Nobody has measured a plasma guggulsterone concentration against the binding constants. The receptor work gives Ki values of 35 nM at MR and 224–315 nM at AR, GR and PR Burris 2005. Whether a 2,000 mg dose of guggulipid puts anywhere near 35 nM of guggulsterone into human plasma decides whether any of that pharmacology is reachable, and it has never been published alongside a dose. One pharmacokinetic study with mass spectrometry settles which half of this page is real.
Nobody has run the thyroid trial. The rat data are 40 years old Tripathi 1984 Tripathi 1988, the human signal is two adverse-event reports Nohr 2009, and no randomized trial of guggul has ever carried TSH, free T4 and free T3 as prespecified endpoints. That is a two-arm, eight-week, hundred-person study with a standard assay panel, and it would answer a question that has been open since the 1980s.
Nobody has separated the two receptors in a person. FXR antagonism and PXR agonism drive CYP7A1 in opposite directions Owsley 2003, and the human read-out of that tug-of-war is measurable: serum 7-alpha-hydroxy-4-cholesten-3-one (C4) is a validated surrogate for CYP7A1 activity and is a single blood draw. Nobody has drawn it on guggul. If C4 rises, FXR won and the LDL rise needs another explanation; if C4 falls, PXR won and the mechanism was inverted all along.
And nobody has tested the interaction the PXR result predicts. PXR is the master transcriptional regulator of CYP3A4 and P-glycoprotein. A PXR agonist Owsley 2003 taken at gram doses is a candidate inducer of the enzyme that clears more than half of all prescribed drugs, and there is no published human interaction study — not with midazolam, not with a statin, not with a contraceptive. The warning on the shelf is real; the measurement behind it does not exist.
Guggul — its own safety story, not its category's
The rash is not a footnote, it is the most reproducible thing guggul does. Six of the 67 participants taking guggulipid developed a hypersensitivity rash; none of the 36 on placebo did Szapary 2003. That is roughly 9% in eight weeks, in a monitored trial, with a clean comparator. Most botanicals produce rash reports at background rates. This one produced them at a rate the trial could detect in fewer than seventy people.
The interaction risk has a named receptor behind it, which is unusual. Guggulsterone activates the pregnane X receptor Owsley 2003. PXR drives transcription of CYP3A4 and P-glycoprotein, and CYP3A4 clears statins, calcium-channel blockers, many antiarrhythmics, most direct oral anticoagulants, tacrolimus and ethinylestradiol. This is not the generic ‘may interact with medications’ line; it is a specific transcriptional mechanism published for this molecule, and the practical reading is that anything with a narrow therapeutic index is a reason not to take guggul at all.
The thyroid caution is the one that should be loudest, and it cuts both ways. Z-guggulsterone raises thyroid peroxidase activity and iodine uptake Tripathi 1984. In somebody on levothyroxine that is a reason to expect a moving TSH; in somebody with an autonomously functioning nodule or latent Graves’ disease it is a reason to expect the wrong direction entirely. Two participants in a 43-person trial reported thyroid adverse effects Nohr 2009. Anyone with thyroid disease, treated or untreated, is in the group this product was never studied in.
The steroid receptor binding is the risk nobody has characterized. A Ki of 35 nM at the mineralocorticoid receptor and 224–315 nM at androgen, glucocorticoid and progesterone receptors Burris 2005 describes a molecule with real affinity for four hormone receptors. Nobody has published aldosterone, renin, cortisol, testosterone or potassium data on a human taking guggul. That is not a reassurance and it is not an alarm; it is an absence, and it should be weighed as one in pregnancy, in hormone-sensitive disease, and alongside spironolactone or eplerenone.
And the harm that is actually most likely is the ordinary one. Somebody with a high LDL who takes guggul instead of a statin spends eight weeks acquiring a 4–5% rise in the number they were trying to lower Szapary 2003. Nothing on this page is as consequential as that arithmetic, and it is the reason the card's own dose line — not recommended on current evidence — is the correct one.
Sources read for this page
- Szapary PO, et al. Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. JAMA 2003;290(6):765-772 · PMID 12915429
- Nohr LA, et al. Resin from the mukul myrrh tree, guggul, can it be used for treating hypercholesterolemia? A randomized, controlled study. Complementary Therapies in Medicine 2009;17(1):16-22 · PMID 19114224
- Urizar NL, et al. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 2002;296(5573):1703-1706 · PMID 11988537
- Burris TP, et al. The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Molecular Pharmacology 2005;67(3):948-954 · PMID 15602004
- Owsley E, Chiang JY. Guggulsterone antagonizes farnesoid X receptor induction of bile salt export pump but activates pregnane X receptor to inhibit cholesterol 7alpha-hydroxylase gene. Biochemical and Biophysical Research Communications 2003;304(1):191-195 · PMID 12705905
- Tripathi YB, et al. Thyroid Stimulating Action of Z-Guggulsterone Obtained from Commiphora mukul. Planta Medica 1984;50(1):78-80 · PMID 17340256
- Tripathi YB, et al. Thyroid stimulatory action of (Z)-guggulsterone: mechanism of action. Planta Medica 1988;54(4):271-277 · PMID 3222368
How you would know if it worked
The traditional claim is lipids, and this is one of the few places in the Vault where a well-conducted trial contradicted the tradition outright: LDL did not fall, and in some participants it rose. That makes the read-out unusually worth running, because the direction you are watching for is the wrong one. Draw ApoB before you start and again a couple of months in — ApoB rather than LDL cholesterol alone because it counts the particles rather than the cargo, and it is the number that decides the argument when the two disagree. A rise is a reason to stop. Two things this list cannot show you: guggul has thyroid effects, so if you take thyroid medication that belongs with your prescriber rather than in a self-test, and the rash and gut upset it can cause will announce themselves without a lab.
- Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) Retest: Every 3–6 months on androgens; annually otherwise.
- ApoB (Apolipoprotein B) Retest: Every 3–6 months on androgens or after any intervention; annually otherwise.
The cheapest panel carrying Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) and at least one other of these is Metabolic Health & Prediabetes, at $90 — the panel is named for a different question, and the marker is the same marker. That is the whole cost of finding out.
Draw before you start, not after. A result with nothing to compare it to answers nothing.
Guggul — safety & side effects
- Digestive upset, headache and skin rash. Rash is more common with guggul than with most botanicals.
- Induces CYP3A4 and P-glycoprotein, so it lowers levels of a long list of medications — statins, propranolol, diltiazem and hormonal contraception among them.
- Affects thyroid hormone conversion; avoid or monitor closely with thyroid disease. Not established as safe in pregnancy or breastfeeding — not because harm is documented, but because these are the two populations systematically excluded from the trials. Absence of data is not reassurance.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Guggul in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Guggul
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| TSH (Thyroid-Stimulating Hormone) | Thyroid sits upstream of most things labeled 'hormonal' |
| Free T4 (Thyroxine) | Distinguishes a real thyroid problem from a borderline TSH |
| Total Testosterone | The baseline, if any of this is aimed at androgens |
| Vitamin D (25-Hydroxy) | Behaves like a hormone and is commonly low |
The Basics — Start Here panel covers these in one order — 4 markers, $32.40 with the discount applied.
Check results you already have → · All 103 markers A–Z
Guggul — frequently asked questions
What is Guggul?
An Ayurvedic resin used for lipids and thyroid. Independent trials did not confirm the traditional lipid claim.
What is the suggested dose of Guggul?
Not recommended on current evidence. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Guggul dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Guggul?
Coach Cam sources Guggul from vetted, top-rated brands on iHerb — use the buy link on this page.
What Guggul is used for
Guggul appears under 2 goals in the goal router.
Related Hormonal & Wellness supplements
Where this goes next
The pages here are the frameworks. The protocols — the dosing, the order to correct things in, the week-by-week schedule and what to retest — are inside Skool.